Table 1.

Problems with Current Strategies to Develop AD Treatment

Mouse studies succeed, but human trials fail

Multiple attempts to use anti-amyloid antibodies by drug companies have been unsuccessful, and some have given up, rather than trying to go in another direction.

No good predictor of who will develop AD. Accurate prediction allows intervention before too much neuronal loss

No way to screen potential treatments for human efficacy other than 5 or 10 years of administering to humans or trying it on animals.

Lack of direct access to the neurons in the brain of the affected individual

No personalized approach or precision medicine as we see for many cancers